ADC Therapeutics (ADC Therapeutics) EV-to-Revenue : 2.92 (As of Apr. 26, 2024)

View and export this data going back to 2020. Start your Free Trial

What is ADC Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, ADC Therapeutics's enterprise value is $203.13 Mil. ADC Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $69.56 Mil. Therefore, ADC Therapeutics's EV-to-Revenue for today is 2.92.

The historical rank and industry rank for ADC Therapeutics's EV-to-Revenue or its related term are showing as below:

ADCT' s EV-to-Revenue Range Over the Past 10 Years
Min: -1.21 Med: 6.38 Max: 1663.47
Current: 2.92

During the past 8 years, the highest EV-to-Revenue of ADC Therapeutics was 1663.47. The lowest was -1.21. And the median was 6.38.

ADCT's EV-to-Revenue is ranked better than
68.25% of 1033 companies
in the Biotechnology industry
Industry Median: 7.68 vs ADCT: 2.92

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-26), ADC Therapeutics's stock price is $4.30. ADC Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.85. Therefore, ADC Therapeutics's PS Ratio for today is 5.05.

ADC Therapeutics EV-to-Revenue Historical Data

The historical data trend for ADC Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADC Therapeutics EV-to-Revenue Chart

ADC Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

36.11

0.48

-0.25

ADC Therapeutics Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															0.48	-0.17	-0.27	-0.92	-0.25

Competitive Comparison of ADC Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, ADC Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ADC Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ADC Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where ADC Therapeutics's EV-to-Revenue falls into.

ADC Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

ADC Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	203.133	/	69.558
	=	2.92

ADC Therapeutics's current Enterprise Value is $203.13 Mil.
ADC Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $69.56 Mil.

ADC Therapeutics (NYSE:ADCT) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

ADC Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	4.30	/	0.852
	=	5.05

ADC Therapeutics's share price for today is $4.30.
ADC Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.85.

ADC Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of ADC Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

ADC Therapeutics (ADC Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066

Website

https://www.adctherapeutics.com

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.